HEADER TRANSFERASE 25-FEB-17 5N9K TITLE CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN TITLE 2 COMPLEX WITH THE ATP-COMPETITIVE, TIGHT-BINDING DIBENZOFURAN TITLE 3 INHIBITOR TF107 (5) COMPND MOL_ID: 1; COMPND 2 MOLECULE: CASEIN KINASE II SUBUNIT ALPHA; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: CK II ALPHA; COMPND 5 EC: 2.7.11.1; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: CSNK2A1, CK2A1; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS PROTEIN KINASE, CK2, CASEIN KINASE 2, PROTEIN PHOSPHORYLATION, ATP- KEYWDS 2 COMPETITIVE INHITITORS, DIBENZOFURAN DERIVATIVES, TRANSFERASE, KEYWDS 3 TIGHT-BINDING INHIBITORS EXPDTA X-RAY DIFFRACTION AUTHOR A.SCHNITZLER,A.GRATZ,A.BOLLACKE,M.WEYRICH,U.KUCKLAENDER,B.WUENSCH, AUTHOR 2 C.GOETZ,K.NIEFIND,J.JOSE REVDAT 5 17-JAN-24 5N9K 1 REMARK REVDAT 4 25-APR-18 5N9K 1 JRNL REVDAT 3 18-APR-18 5N9K 1 JRNL REVDAT 2 07-MAR-18 5N9K 1 JRNL REVDAT 1 28-FEB-18 5N9K 0 JRNL AUTH A.SCHNITZLER,A.GRATZ,A.BOLLACKE,M.WEYRICH,U.KUCKLANDER, JRNL AUTH 2 B.WUNSCH,C.GOTZ,K.NIEFIND,J.JOSE JRNL TITL A PI-HALOGEN BOND OF DIBENZOFURANONES WITH THE GATEKEEPER JRNL TITL 2 PHE113 IN HUMAN PROTEIN KINASE CK2 LEADS TO POTENT TIGHT JRNL TITL 3 BINDING INHIBITORS. JRNL REF PHARMACEUTICALS V. 11 2018 JRNL REFN ESSN 1424-8247 JRNL PMID 29462988 JRNL DOI 10.3390/PH11010023 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH I.ERMAKOVA,B.BOLDYREFF,O.G.ISSINGER,K.NIEFIND REMARK 1 TITL CRYSTAL STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN REMARK 1 TITL 2 PROTEIN KINASE CK2 CATALYTIC SUBUNIT. REMARK 1 REF J. MOL. BIOL. V. 330 925 2003 REMARK 1 REFN ISSN 0022-2836 REMARK 1 PMID 12860116 REMARK 1 DOI 10.1016/S0022-2836(03)00638-7 REMARK 1 REFERENCE 2 REMARK 1 AUTH C.W.YDE,I.ERMAKOVA,O.G.ISSINGER,K.NIEFIND REMARK 1 TITL INCLINING THE PURINE BASE BINDING PLANE IN PROTEIN KINASE REMARK 1 TITL 2 CK2 BY EXCHANGING THE FLANKING SIDE-CHAINS GENERATES A REMARK 1 TITL 3 PREFERENCE FOR ATP AS A COSUBSTRATE. REMARK 1 REF J. MOL. BIOL. V. 347 399 2005 REMARK 1 REFN ISSN 0022-2836 REMARK 1 PMID 15740749 REMARK 1 DOI 10.1016/J.JMB.2005.01.003 REMARK 1 REFERENCE 3 REMARK 1 AUTH K.NIEFIND,N.BISCHOFF,A.G.GOLUB,V.G.BDZHOLA,A.O.BALANDA, REMARK 1 AUTH 2 A.O.PRYKHOD'KO,S.M.YARMOLUK REMARK 1 TITL STRUCTURAL HYPERVARIABILITY OF THE TWO HUMAN PROTEIN KINASE REMARK 1 TITL 2 CK2 CATALYTIC SUBUNIT PARALOGS REVEALED BY COMPLEX REMARK 1 TITL 3 STRUCTURES WITH A FLAVONOL- AND A REMARK 1 TITL 4 THIENO[2,3-D]PYRIMIDINE-BASED INHIBITOR. REMARK 1 REF PHARMACEUTICALS (BASEL) V. 10 2017 REMARK 1 REFN ESSN 1424-8247 REMARK 1 PMID 28085026 REMARK 1 DOI 10.3390/PH10010009 REMARK 1 REFERENCE 4 REMARK 1 AUTH C.GOETZ,A.GRATZ,U.KUCKLAENDER,J.JOSE REMARK 1 TITL TF--A NOVEL CELL-PERMEABLE AND SELECTIVE INHIBITOR OF HUMAN REMARK 1 TITL 2 PROTEIN KINASE CK2 INDUCES APOPTOSIS IN THE PROSTATE CANCER REMARK 1 TITL 3 CELL LINE LNCAP. REMARK 1 REF BIOCHIM. BIOPHYS. ACTA V.1820 970 2012 REMARK 1 REFN ISSN 0006-3002 REMARK 1 PMID 22387500 REMARK 1 DOI 10.1016/J.BBAGEN.2012.02.009 REMARK 2 REMARK 2 RESOLUTION. 1.64 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX (1.11.1_2575: ???) REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.64 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 36.22 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.350 REMARK 3 COMPLETENESS FOR RANGE (%) : 98.9 REMARK 3 NUMBER OF REFLECTIONS : 37635 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.165 REMARK 3 R VALUE (WORKING SET) : 0.164 REMARK 3 FREE R VALUE : 0.184 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.850 REMARK 3 FREE R VALUE TEST SET COUNT : 1826 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 36.2287 - 3.8623 0.99 2864 129 0.1455 0.1577 REMARK 3 2 3.8623 - 3.0662 0.99 2801 134 0.1427 0.1566 REMARK 3 3 3.0662 - 2.6787 0.99 2794 143 0.1654 0.1999 REMARK 3 4 2.6787 - 2.4339 1.00 2784 134 0.1670 0.1750 REMARK 3 5 2.4339 - 2.2594 1.00 2784 139 0.1612 0.1922 REMARK 3 6 2.2594 - 2.1262 1.00 2753 140 0.1631 0.1885 REMARK 3 7 2.1262 - 2.0198 0.99 2781 132 0.1709 0.1845 REMARK 3 8 2.0198 - 1.9319 1.00 2711 162 0.1792 0.2118 REMARK 3 9 1.9319 - 1.8575 0.99 2764 138 0.1880 0.2153 REMARK 3 10 1.8575 - 1.7934 1.00 2776 161 0.2018 0.2279 REMARK 3 11 1.7934 - 1.7373 1.00 2759 133 0.2336 0.2399 REMARK 3 12 1.7373 - 1.6877 1.00 2734 142 0.2539 0.2730 REMARK 3 13 1.6877 - 1.6432 0.91 2504 139 0.2859 0.2994 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : NULL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.180 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 19.760 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.004 2977 REMARK 3 ANGLE : 0.680 4030 REMARK 3 CHIRALITY : 0.049 409 REMARK 3 PLANARITY : 0.004 523 REMARK 3 DIHEDRAL : 12.834 1764 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 6 REMARK 3 TLS GROUP : 1 REMARK 3 SELECTION: CHAIN 'A' AND (RESID 2 THROUGH 24 ) REMARK 3 ORIGIN FOR THE GROUP (A): -3.5642 -10.0334 48.2132 REMARK 3 T TENSOR REMARK 3 T11: 0.3519 T22: 0.2353 REMARK 3 T33: 0.4004 T12: -0.0503 REMARK 3 T13: -0.0390 T23: 0.0868 REMARK 3 L TENSOR REMARK 3 L11: 3.5709 L22: 1.5586 REMARK 3 L33: 3.2557 L12: -0.6121 REMARK 3 L13: -0.2090 L23: 0.3647 REMARK 3 S TENSOR REMARK 3 S11: -0.0152 S12: -0.3279 S13: -0.6838 REMARK 3 S21: -0.1118 S22: 0.0007 S23: 0.2196 REMARK 3 S31: 0.5867 S32: -0.3318 S33: 0.0450 REMARK 3 TLS GROUP : 2 REMARK 3 SELECTION: CHAIN 'A' AND (RESID 25 THROUGH 58 ) REMARK 3 ORIGIN FOR THE GROUP (A): -25.7154 10.2495 44.7689 REMARK 3 T TENSOR REMARK 3 T11: 0.2303 T22: 0.4829 REMARK 3 T33: 0.3538 T12: -0.0754 REMARK 3 T13: 0.0046 T23: 0.0719 REMARK 3 L TENSOR REMARK 3 L11: 2.5019 L22: 5.1179 REMARK 3 L33: 1.9946 L12: -2.0102 REMARK 3 L13: 0.2748 L23: 0.9429 REMARK 3 S TENSOR REMARK 3 S11: 0.0875 S12: -0.0451 S13: -0.3050 REMARK 3 S21: 0.1674 S22: -0.2413 S23: 0.3429 REMARK 3 S31: 0.1366 S32: -0.5430 S33: 0.1027 REMARK 3 TLS GROUP : 3 REMARK 3 SELECTION: CHAIN 'A' AND (RESID 59 THROUGH 108 ) REMARK 3 ORIGIN FOR THE GROUP (A): -22.5459 6.8253 47.0264 REMARK 3 T TENSOR REMARK 3 T11: 0.1639 T22: 0.3886 REMARK 3 T33: 0.3140 T12: -0.0470 REMARK 3 T13: 0.0153 T23: 0.0809 REMARK 3 L TENSOR REMARK 3 L11: 4.1093 L22: 1.8807 REMARK 3 L33: 1.0563 L12: -1.5712 REMARK 3 L13: 1.0697 L23: -0.9564 REMARK 3 S TENSOR REMARK 3 S11: 0.0660 S12: -0.2369 S13: -0.4033 REMARK 3 S21: -0.0259 S22: 0.0417 S23: 0.3863 REMARK 3 S31: 0.0451 S32: -0.2902 S33: -0.1099 REMARK 3 TLS GROUP : 4 REMARK 3 SELECTION: CHAIN 'A' AND (RESID 109 THROUGH 149 ) REMARK 3 ORIGIN FOR THE GROUP (A): -5.5952 16.7246 51.2002 REMARK 3 T TENSOR REMARK 3 T11: 0.2385 T22: 0.2942 REMARK 3 T33: 0.2416 T12: 0.0149 REMARK 3 T13: 0.0161 T23: 0.0411 REMARK 3 L TENSOR REMARK 3 L11: 3.2310 L22: 1.4188 REMARK 3 L33: 0.9597 L12: 1.5302 REMARK 3 L13: 0.6225 L23: 0.8204 REMARK 3 S TENSOR REMARK 3 S11: -0.1831 S12: -0.1816 S13: 0.4115 REMARK 3 S21: -0.1162 S22: 0.1769 S23: 0.2730 REMARK 3 S31: -0.1909 S32: -0.1451 S33: -0.0146 REMARK 3 TLS GROUP : 5 REMARK 3 SELECTION: CHAIN 'A' AND (RESID 150 THROUGH 280 ) REMARK 3 ORIGIN FOR THE GROUP (A): 1.9837 7.5526 37.7500 REMARK 3 T TENSOR REMARK 3 T11: 0.1731 T22: 0.1319 REMARK 3 T33: 0.1572 T12: -0.0011 REMARK 3 T13: -0.0194 T23: 0.0302 REMARK 3 L TENSOR REMARK 3 L11: 2.0252 L22: 1.2773 REMARK 3 L33: 1.9435 L12: 0.0984 REMARK 3 L13: -0.1302 L23: 0.2236 REMARK 3 S TENSOR REMARK 3 S11: 0.0318 S12: -0.0070 S13: -0.0170 REMARK 3 S21: -0.1533 S22: 0.0058 S23: 0.0621 REMARK 3 S31: -0.0394 S32: 0.0172 S33: -0.0437 REMARK 3 TLS GROUP : 6 REMARK 3 SELECTION: CHAIN 'A' AND (RESID 281 THROUGH 330 ) REMARK 3 ORIGIN FOR THE GROUP (A): 10.2825 13.4585 49.4208 REMARK 3 T TENSOR REMARK 3 T11: 0.1258 T22: 0.2111 REMARK 3 T33: 0.1797 T12: -0.0064 REMARK 3 T13: 0.0136 T23: 0.0026 REMARK 3 L TENSOR REMARK 3 L11: 1.3013 L22: 3.7681 REMARK 3 L33: 2.1301 L12: -0.0892 REMARK 3 L13: 0.4237 L23: 0.7781 REMARK 3 S TENSOR REMARK 3 S11: 0.0101 S12: -0.1480 S13: 0.0628 REMARK 3 S21: 0.0041 S22: 0.0343 S23: -0.1400 REMARK 3 S31: -0.1029 S32: 0.1889 S33: -0.0412 REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 5N9K COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 25-FEB-17. REMARK 100 THE DEPOSITION ID IS D_1200003732. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 12-OCT-12 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 5.6 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SLS REMARK 200 BEAMLINE : X06DA REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.99987 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 2M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : AIMLESS REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 37660 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.640 REMARK 200 RESOLUTION RANGE LOW (A) : 45.670 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.0 REMARK 200 DATA REDUNDANCY : 3.300 REMARK 200 R MERGE (I) : 0.03600 REMARK 200 R SYM (I) : 0.03600 REMARK 200 FOR THE DATA SET : 17.0000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.64 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.67 REMARK 200 COMPLETENESS FOR SHELL (%) : 87.0 REMARK 200 DATA REDUNDANCY IN SHELL : 2.80 REMARK 200 R MERGE FOR SHELL (I) : 0.64500 REMARK 200 R SYM FOR SHELL (I) : 0.64500 REMARK 200 FOR SHELL : 1.600 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: 2PVR REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 37.29 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 1.96 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PRIOR TO THE CRYSTALLIZATION THE REMARK 280 INHIBITOR WAS SOLUBILIZED IN 100 % DMSO IN A CONCENTRATION OF 10 REMARK 280 MM. THEN, THIS INHIBITOR STOCK SOLUTION WAS MIXED IN A RATIO OF REMARK 280 1:10 WITH HUMAN CK2ALPHA (CONSTRUCT 1-335; SOLVED WITH A PROTEIN REMARK 280 CONCENTRATION OF 8-10 MG/ML IN 500 MM SODIUM CHLORIDE, 25 MM REMARK 280 TRIS/HCL PH 8.5). AFTER A SHORT TIME OF INCUBATION THIS MIXTURE REMARK 280 WERE MIXED WITH RESERVOIR SOLUTION [32 % (W/V) PEG4000, 0.2 M REMARK 280 AMMONIUM ACETATE, 0.1 M CITRATE PH 5.6] IN A RATIO OF 2.5:1. 3.5 REMARK 280 MICROLITER OF THIS FINAL MIXTURE WAS THEN EQUILIBRATED AGAINST REMARK 280 THE RESERVOIR SOLUTION. THE CRYSTAL GROWTH WAS INDUCED BY REMARK 280 SEEDING WITH 150 NANOLITER SEED SUSPENSION AFTER AN REMARK 280 EQUILIBRATION TIME OF TWO DAYS., VAPOR DIFFUSION, SITTING DROP, REMARK 280 TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 22.83500 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1450 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 15500 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -2.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 1 REMARK 465 GLN A 331 REMARK 465 ALA A 332 REMARK 465 ARG A 333 REMARK 465 MET A 334 REMARK 465 GLY A 335 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASN A 61 15.95 -146.29 REMARK 500 ASP A 156 43.26 -148.19 REMARK 500 ASP A 175 77.23 42.81 REMARK 500 ALA A 193 163.73 60.58 REMARK 500 MET A 208 57.74 -93.89 REMARK 500 HIS A 234 73.01 -105.91 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue 8QK A 401 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue ACT A 402 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue ACT A 403 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue ACT A 404 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue ACT A 405 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue ACT A 406 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC7 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue ACT A 407 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC8 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue GOL A 408 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 5N9L RELATED DB: PDB REMARK 900 RELATED ID: 5N9N RELATED DB: PDB DBREF 5N9K A 1 335 UNP P68400 CSK21_HUMAN 1 335 SEQRES 1 A 335 MET SER GLY PRO VAL PRO SER ARG ALA ARG VAL TYR THR SEQRES 2 A 335 ASP VAL ASN THR HIS ARG PRO ARG GLU TYR TRP ASP TYR SEQRES 3 A 335 GLU SER HIS VAL VAL GLU TRP GLY ASN GLN ASP ASP TYR SEQRES 4 A 335 GLN LEU VAL ARG LYS LEU GLY ARG GLY LYS TYR SER GLU SEQRES 5 A 335 VAL PHE GLU ALA ILE ASN ILE THR ASN ASN GLU LYS VAL SEQRES 6 A 335 VAL VAL LYS ILE LEU LYS PRO VAL LYS LYS LYS LYS ILE SEQRES 7 A 335 LYS ARG GLU ILE LYS ILE LEU GLU ASN LEU ARG GLY GLY SEQRES 8 A 335 PRO ASN ILE ILE THR LEU ALA ASP ILE VAL LYS ASP PRO SEQRES 9 A 335 VAL SER ARG THR PRO ALA LEU VAL PHE GLU HIS VAL ASN SEQRES 10 A 335 ASN THR ASP PHE LYS GLN LEU TYR GLN THR LEU THR ASP SEQRES 11 A 335 TYR ASP ILE ARG PHE TYR MET TYR GLU ILE LEU LYS ALA SEQRES 12 A 335 LEU ASP TYR CYS HIS SER MET GLY ILE MET HIS ARG ASP SEQRES 13 A 335 VAL LYS PRO HIS ASN VAL MET ILE ASP HIS GLU HIS ARG SEQRES 14 A 335 LYS LEU ARG LEU ILE ASP TRP GLY LEU ALA GLU PHE TYR SEQRES 15 A 335 HIS PRO GLY GLN GLU TYR ASN VAL ARG VAL ALA SER ARG SEQRES 16 A 335 TYR PHE LYS GLY PRO GLU LEU LEU VAL ASP TYR GLN MET SEQRES 17 A 335 TYR ASP TYR SER LEU ASP MET TRP SER LEU GLY CYS MET SEQRES 18 A 335 LEU ALA SER MET ILE PHE ARG LYS GLU PRO PHE PHE HIS SEQRES 19 A 335 GLY HIS ASP ASN TYR ASP GLN LEU VAL ARG ILE ALA LYS SEQRES 20 A 335 VAL LEU GLY THR GLU ASP LEU TYR ASP TYR ILE ASP LYS SEQRES 21 A 335 TYR ASN ILE GLU LEU ASP PRO ARG PHE ASN ASP ILE LEU SEQRES 22 A 335 GLY ARG HIS SER ARG LYS ARG TRP GLU ARG PHE VAL HIS SEQRES 23 A 335 SER GLU ASN GLN HIS LEU VAL SER PRO GLU ALA LEU ASP SEQRES 24 A 335 PHE LEU ASP LYS LEU LEU ARG TYR ASP HIS GLN SER ARG SEQRES 25 A 335 LEU THR ALA ARG GLU ALA MET GLU HIS PRO TYR PHE TYR SEQRES 26 A 335 THR VAL VAL LYS ASP GLN ALA ARG MET GLY HET 8QK A 401 27 HET ACT A 402 4 HET ACT A 403 4 HET ACT A 404 4 HET ACT A 405 4 HET ACT A 406 4 HET ACT A 407 4 HET GOL A 408 6 HETNAM 8QK 1,3-BIS(CHLORANYL)-6-[(~{E})-(4-METHOXYPHENYL) HETNAM 2 8QK IMINOMETHYL]DIBENZOFURAN-2,7-DIOL HETNAM ACT ACETATE ION HETNAM GOL GLYCEROL HETSYN GOL GLYCERIN; PROPANE-1,2,3-TRIOL FORMUL 2 8QK C20 H13 CL2 N O4 FORMUL 3 ACT 6(C2 H3 O2 1-) FORMUL 9 GOL C3 H8 O3 FORMUL 10 HOH *249(H2 O) HELIX 1 AA1 PRO A 20 ASP A 25 1 6 HELIX 2 AA2 TYR A 26 HIS A 29 5 4 HELIX 3 AA3 ASN A 35 ASP A 37 5 3 HELIX 4 AA4 LYS A 74 ARG A 89 1 16 HELIX 5 AA5 ASP A 120 TYR A 125 1 6 HELIX 6 AA6 GLN A 126 LEU A 128 5 3 HELIX 7 AA7 THR A 129 MET A 150 1 22 HELIX 8 AA8 LYS A 158 HIS A 160 5 3 HELIX 9 AA9 SER A 194 LYS A 198 5 5 HELIX 10 AB1 GLY A 199 VAL A 204 1 6 HELIX 11 AB2 TYR A 211 ARG A 228 1 18 HELIX 12 AB3 ASP A 237 GLY A 250 1 14 HELIX 13 AB4 GLY A 250 TYR A 261 1 12 HELIX 14 AB5 ASP A 266 ILE A 272 5 7 HELIX 15 AB6 ARG A 280 VAL A 285 5 6 HELIX 16 AB7 ASN A 289 VAL A 293 5 5 HELIX 17 AB8 SER A 294 LEU A 305 1 12 HELIX 18 AB9 ASP A 308 ARG A 312 5 5 HELIX 19 AC1 THR A 314 GLU A 320 1 7 HELIX 20 AC2 HIS A 321 TYR A 325 5 5 SHEET 1 AA1 5 TYR A 39 ARG A 47 0 SHEET 2 AA1 5 SER A 51 ASN A 58 -1 O VAL A 53 N LEU A 45 SHEET 3 AA1 5 LYS A 64 LEU A 70 -1 O ILE A 69 N GLU A 52 SHEET 4 AA1 5 PRO A 109 GLU A 114 -1 O PHE A 113 N VAL A 66 SHEET 5 AA1 5 LEU A 97 LYS A 102 -1 N VAL A 101 O ALA A 110 SHEET 1 AA2 2 ILE A 152 MET A 153 0 SHEET 2 AA2 2 GLU A 180 PHE A 181 -1 O GLU A 180 N MET A 153 SHEET 1 AA3 2 VAL A 162 ASP A 165 0 SHEET 2 AA3 2 LYS A 170 LEU A 173 -1 O LYS A 170 N ASP A 165 CISPEP 1 GLU A 230 PRO A 231 0 -3.93 SITE 1 AC1 14 ARG A 21 ARG A 43 LEU A 45 VAL A 66 SITE 2 AC1 14 LYS A 68 PHE A 113 GLU A 114 VAL A 116 SITE 3 AC1 14 MET A 163 ILE A 174 ASP A 175 ACT A 406 SITE 4 AC1 14 GOL A 408 HOH A 630 SITE 1 AC2 5 GLN A 36 ASP A 103 PRO A 104 ALA A 110 SITE 2 AC2 5 ARG A 280 SITE 1 AC3 1 ASN A 62 SITE 1 AC4 4 GLY A 91 ASN A 93 ILE A 94 ARG A 172 SITE 1 AC5 3 ARG A 80 ARG A 155 LEU A 178 SITE 1 AC6 3 HIS A 160 8QK A 401 GOL A 408 SITE 1 AC7 3 ARG A 316 MET A 319 HOH A 530 SITE 1 AC8 7 ARG A 47 GLY A 48 SER A 51 HIS A 160 SITE 2 AC8 7 8QK A 401 ACT A 406 HOH A 587 CRYST1 57.876 45.670 63.753 90.00 111.14 90.00 P 1 21 1 2 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017278 0.000000 0.006681 0.00000 SCALE2 0.000000 0.021896 0.000000 0.00000 SCALE3 0.000000 0.000000 0.016817 0.00000